A Multicenter Randomized Controlled Study of the Effect of Laparoscopic Preservation of the Pylorus

A Multicenter Randomized Controlled Study of the Effect of Laparoscopic Preservation of the Pylorus and Vagus Nerve on the Postoperative Quality of Life in Patients With Early Gastric Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04164095

Enrollment

160

Registered

2019-11-15

Start date

2020-01-01

Completion date

2025-12-31

Last updated

2019-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quality of Life

Brief summary

For the patients with early gastric cancer (T1), preoperative evaluation (gastroscope, ultrasound gastroscope and abdominal enhanced CT) showed that the tumor was located in the body of the stomach, and the margin was enough to retain the pylorus and non lymph node metastasis (N0). Lappg (D1 + lymph node dissection) and traditional laparoscopic distal gastrectomy (BII type anastomosis, D1 + lymph node dissection) were included A control study was conducted to evaluate the influence of two surgical methods on the long-term quality of life of patients after operation

Interventions

PROCEDURElappg

Preservation of pylorus and vagus nerve by laparoscopy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. 18 years old \< age \< 75 years old; 2. primary gastric lesions were diagnosed as gastric adenocarcinoma by biopsy; 3. the preoperative clinical stage was T1N0M0 according to ajcc-7thtnm; 4. it is predicted that R0 can be obtained by pylorogastric gastrectomy and D1 + lymph node dissection; 5. preoperative ECoG physical state score 0 / 1; 6. preoperative ASA score I-III; 7. informed consent of patients.

Exclusion criteria

1. pregnant or lactating women; suffering from serious mental illness; 2. the history of upper abdominal surgery (except laparoscopic cholecystectomy); 3. history of gastric surgery (including ESD / EMR for gastric cancer); 4. preoperative imaging examination showed regional enlarged lymph nodes; 5. having other malignant diseases within 5 years; 6. patients with gastric cancer who have received new adjuvant therapy or recommended new adjuvant therapy; 7. there was a history of unstable angina or myocardial infarction within 6 months; 8. have a history of cerebral infarction or cerebral hemorrhage within 6 months; 9. there was a history of continuous systemic corticosteroid therapy within 1 month; 10. simultaneous surgical treatment of other diseases is needed; 11. gastric cancer with complications (hemorrhage, perforation, obstruction) requires emergency surgery; 12. FEV1 of pulmonary function examination was less than 50% of the predicted value.

Design outcomes

Primary

Measure	Time frame	Description
EORTC-QLQ-C30	5 years	score: 0-100. more global and functional scales is better. less symptom scales is better

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026